pmcc logo sml



Here are the staff publications for May 2019.

Compiled by the Health Sciences Library (RMH, RWH, PMCC and Victorian Mental Health) 3rd Jun 2019.


1. Alexander M, Sryjanen R, Ball D, MacManus M, Burbury K. The potential "additive" thromboembolic risk of radiotherapy. Asia-Pacific Journal of Clinical Oncology 2019;15:183-4.

2. Alfano CM, Jefford M, Maher J, Birken SA, Mayer DK. Building Personalized Cancer Follow-up Care Pathways in the United States: Lessons Learned From Implementation in England, Northern Ireland, and Australia. American Society of Clinical Oncology Education Book 2019;39:625-39.

3. Bast RC, Jr., Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Jr., Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer 2019;125:1963-72.

4. Beatty L, Kemp E, Coll JR, Turner J, Butow P, Milne D, Yates P, Lambert S, Wootten A, Yip D, Koczwara B. Finding My Way: results of a multicentre RCT evaluating a web-based self-guided psychosocial intervention for newly diagnosed cancer survivors. Supportive Care in Cancer 2019;27:2533-44.

5. Blaschke SM, Schofield P, Taylor K, Ugalde A. Common dedication to facilitating good dying experiences: Qualitative study of end-of-life care professionals' attitudes towards voluntary assisted dying. Palliative Medicine 2019;33:562-9.

6. Brandao RD, Mensaert K, Lopez-Perolio I, Tserpelis D, Xenakis M, Lattimore V, Walker LC, Kvist A, Vega A, Gutierrez-Enriquez S, Diez O, de la Hoya M, Spurdle AB, De Meyer T, Blok MJ. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes. International Journal of Cancer 2019;145:401-14.

7. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 2019;133:2031-42.

8. Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG. Molecular comparison of interval and screen-detected breast cancers. The Journal of Pathology 2019;248:243-52.

9. Chew SM, Sweeney N, Kidd SE, Reed C. Candida auris arriving on our shores: an Australian microbiology laboratory's experience. Pathology 2019;51:431-3.

10. Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh BS, Lo SS, Muacevic A, Siva S. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. The Journal of Urology 2019;201:1097-104.

11. Curchin DJ, Forward E, Dickison P, Harris VR, McCormack CJ, Smith SD. The acceleration of melanoma in situ: A population-based study of melanoma incidence trends from Victoria, Australia, 1985-2015. Journal of the American Academy of Dermatology 2019;80:1791-3.

12. Devchand M, Kirkpatrick CMJ, Stevenson W, Garrett K, Perera D, Khumra S, Urbancic K, Grayson ML, Trubiano JA. Evaluation of a pharmacist-led penicillin allergy de-labelling ward round: a novel antimicrobial stewardship intervention. The Journal of Antimicrobial Chemotherapy 2019;74:1725-30.

13. Duncan C, Omran GJ, Teh J, Davis NF, Bolton DM, Lawrentschuk N. Erectile dysfunction: a global review of intracavernosal injectables. World Journal of Urology 2019;37:1007-14.

14. Farshid G, Bilous M, Morey A, Fox S, Lakhani S, Loi S, Bell R, Spillane A. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. Pathology 2019;51:345-8.

15. Ferreira G, Iravani A, Hofman MS, Hicks RJ. Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution. Cancer Imaging 2019;19:23.

16. Foroughi S, Wong HL, Gately L, Lee M, Simons K, Tie J, Burgess AW, Gibbs P. Registry-based randomized clinical trials as a method to improve cancer care in Australia. Asia-Pacific Journal of Clinical Oncology 2019;15:188-9.

17. Fortuno C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, Haupt Y, Haupt S, Study ISK, Tucker K, Spurdle AB, Thomas DM, James PA. A quantitative model to predict pathogenicity of missense variants in the TP53 gene. Human Mutation 2019;40:788-800.

18. Goldie SJ, Chincarini G, Darido C. Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma. International Journal of Molecular Sciences 2019;20.

19. Hung TJ, McLean L, Mitchell C, Pascoe C, Lawrentschuk N, Murphy DG, Iravani A, Singh D, Hofman MS, Zidan L, Akhurst T, Lewin J, Hicks RJ. The role of (18)F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball! Cancer Imaging 2019;19:28.

20. Jones JRA, Berney S, Connolly B, Waterland JL, Denehy L, Griffith DM, Puthucheary ZA. Socioeconomic Position and Health Outcomes Following Critical Illness: A Systematic Review. Critical Care Medicine 2019;47:e512-e21.

21. Keighley C, Chen SC, Marriott D, Pope A, Chapman B, Kennedy K, Bak N, Underwood N, Wilson HL, McDonald K, Darvall J, Halliday C, Kidd S, Nguyen Q, Hajkowicz K, Sorrell TC, Van Hal S, Slavin MA. Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study. BMC Infectious Diseases 2019;19:445.

22. Kerage D, Sloan EK, Mattarollo SR, McCombe PA. Interaction of neurotransmitters and neurochemicals with lymphocytes. Journal of Neuroimmunology 2019;332:99-111.

23. Kiss N, Beraldo J, Everitt S. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival. Supportive Care in Cancer 2019;27:2657-64.

24. Lawrentschuk N. Editorial Comment. The Journal of Urology 2019;201:1104.

25. Mardiana S, Lai J, House IG, Beavis PA, Darcy PK. Switching on the green light for chimeric antigen receptor T-cell therapy. Clinical & Translational Immunology 2019;8:e1046.

26. Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. British Journal of Cancer 2019;120:1075-82.

27. Murphy DG, Azad AA, Sandhu S, Violet J, Hofman MS. Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. European Urology 2019;75:927-8.

28. Parente P, Chan BA, Hughes BGM, Jasas K, Joshi R, Kao S, Hegi-Johnson F, Hui R, McLaughlin-Barrett S, Nordman I, Stone E. Patterns of care for stage III non-small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology 2019;15:93-100.

29. Reynolds HM, Williams S, Jackson P, Mitchell C, Hofman MS, Hicks RJ, Murphy DG, Haworth A. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BJU International 2019;123:1020-30.

30. Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of Clinical Oncology 2019;37:1159-68.

31. Russell L, Ugalde A, Orellana L, Milne D, Krishnasamy M, Chambers R, Austin DW, Livingston PM. A pilot randomised controlled trial of an online mindfulness-based program for people diagnosed with melanoma. Supportive Care in Cancer 2019;27:2735-46.

32. Saner FAM, Herschtal A, Nelson BH, deFazio A, Goode EL, Ramus SJ, Pandey A, Beach JA, Fereday S, Berchuck A, Lheureux S, Pearce CL, Pharoah PD, Pike MC, Garsed DW, Bowtell DDL. Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews: Cancer 2019;19:339-48.

33. Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European Urology 2019;75:910-7.

34. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2019;37:1370-9.

35. Smith P, Godde N, Rubio S, Tekeste M, Vladar EK, Axelrod JD, Henderson DJ, Milgrom-Hoffman M, Humbert PO, Hinck L. VANGL2 regulates luminal epithelial organization and cell turnover in the mammary gland. Scientific Reports 2019;9:7079.

36. Steiner E, Shieh CC, Caillet V, Booth J, O'Brien R, Briggs A, Hardcastle N, Jayamanne D, Szymura K, Eade T, Keall P. Both four-dimensional computed tomography and four-dimensional cone beam computed tomography under-predict lung target motion during radiotherapy. Radiotherapy and Oncology 2019;135:65-73.

37. Teh J, Wei J, Chiang G, Nzenza TC, Bolton D, Lawrentschuk N. Men's health on the web: an analysis of current resources. World Journal of Urology 2019;37:1043-7.

38. Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. Histopathology 2019;74:1025-35.

39. Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, Andre F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. Journal of Clinical Oncology 2019;37:1169-78.

40. Wiede F, Brodnicki TC, Goh PK, Leong YA, Jones GW, Yu D, Baxter AG, Jones SA, Kay TWH, Tiganis T. T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities. Diabetes 2019;68:1251-66.

41. Wong R, Tie J, Lee M, Cohen J, Wang Y, Li L, Ma S, Christie M, Kosmider S, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. International Journal of Cancer 2019;145:540-7.

42. Youens D, Halkett G, Wright C, O'Connor M, Schofield P, Jefford M, Aranda S, Kane R, Moorin R, team RTPp. Assessing the cost-effectiveness of RT Prepare: A radiation therapist-delivered intervention for reducing psychological distress prior to radiotherapy. Psycho-Oncology 2019;28:1110-8.

43. Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, Liao Y, Kehm RD, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, John EM, Hopper JL, Terry MB. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. International Journal of Cancer 2019;145:370-9.